Business Wire

CA-EBD/BIOPHARM-AMERICA

Del
BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

The seventh annual BioPharm America™ international life science partnering conference will kick off in a less than two weeks, September 22–24, at Boston Marriott Copley Place in the center of Boston’s historic Back Bay.

The highly reputable life science partnering event will draw biotech and pharma executives from around the world to identify and enter into strategic relationships that ultimately drive the multibillion dollar drug development industry. The Boston event is uniquely known to draw innovative biotech companies from the region and abroad, as well as pharma and finance companies actively seeking new partners.

The first day features a compelling Keynote and Opening Plenary, followed by a strong program that is sure to drive partnering activity.

A major draw to precede Monday’s Keynote address is the live announcement of the Fierce 15 by John Carroll , Editor-in-Chief of FierceBiotech. The Fierce 15 is a hunt that involves the biggest ideas in biotech, the most daring characters in biopharma, and entrepreneurs doing things that haven't been done before. The result is fifteen privately held drug developers or platform biotechs with the potential to have a huge impact on the treatment of human diseases. A LIVE Stream announcement of the Fierce 15 will take place during BioPharm America™ 2014 on partnering360:Insight LIVE on September 22, 2014 at 10:45 a.m. EDT.

The Keynote address will be given by Gary Nabel , Chief Scientific Officer at Sanofi, who will also join the Opening Plenary moderated by Karen Bernstein , Co-Founder, Chairman, and Editor-in-Chief at BioCentury on the topic “Getting real: Biopharma innovation and its impact on patients,” with additional panelists Barry Greene , President and COO at Alnylam Pharmaceuticals; Adam M. Koppel , Senior VP and Chief Strategy Officer at Biogen Idec; and Richard Pops , Chairman and CEO at Alkermes plc.

“These are exciting times, because pharma companies are going back to their roots. There’s been a major shift toward external innovation and data-driven science that guides the development of new medicines. For academic research, we see more collaboration at earlier stages. For biotech, we see relationships built at different points in the evolution of new medicines, and we are using structures and support that incentivize both partners to achieve success,” said Nabel.

Global pharmaceutical companies already confirmed to send business development teams to BioPharm America include AstraZeneca; Bayer HealthCare; Bristol-Myers Squibb; EMD Serono; Merck; Novo Nordisk; Sanofi; and Shire.

BioPharm America is produced by EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) to facilitate strategic collaborations with leading companies. One-to-one networking at BioPharm America™ is powered by partneringONE® , the leading conference networking solution for the life sciences.

Register now to attend the largest dedicated partnering event in the eastern US. Partnering is already open.

To join the conversation:

Visit: BioPharm America™ webpage

Follow: @EBDGroup No. BPA14

Talk: Life Science Partnering group

News: partnering360.com/insight

Watch: youtube.com/EBDGROUPChannel

Blog: partnering360.com/blog/

About BioPharm America 2014

BioPharm America™ is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

Join partnering360® to kick off your partnering activities before BioPharm America, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round.

Notes to Editors:

Entry to BioPharm America 2014 is free to members of the press, including full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Members of the media can get registration information on the press registration information page .

An Online Press Kit service for BioPharm America™ 2014 is available to enhance your public relations efforts.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America ™, the fastest growing partnering event in North America
  • Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
  • The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com .

About MassBio

www.massbio.org

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

Contact:

EBD Group
Erin Righetti, +1-760-930-0500
erighetti@ebdgroup.com
or
MassBio
Jessica Roche, +1-617-674-5146
jessica.roche@massbio.org

Link:

Multimedia Gallery

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 10:46:00 CEST | Press release

In just four months, Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programm

Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 08:00:00 CEST | Press release

Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye